It’s well-known that randomized controlled trials (RCTs) are the most trusted method for life sciences companies to study the efficacy of new treatments. But RCTs are expensive and time-consuming, and oftentimes the data isn’t leveraged after the trial ends. So what does the future hold for clinical trial design? Can the costs of RCTs be reduced? And how can predictive analytics help make trials and trial design more efficient?

 

In this article in Applied Clinical Trials, ZS’s Venkat Sethuraman was tapped to share his perspective on emerging trends in the clinical design space, and how those trending concepts could improve clinical trial design without undermining RCTs.

For more information, please contact our media relations team.

Contact
 

Susan Brophy

Golin

zsmediateam@golin.com

312.729.4359